- Positive Results From Phase 2 Study of Once-weekly FluidCrystal® Formulation of Setmelanotide in Healthy Volunteers With Obesity
- Camurus Raises Full Year 2020 Revenue Guidance
- Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US
- Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid Dependence
- Camurus' Interim Report January-March 2020
Camurus AB (7CA:STU) closed at 15.16, -0.52% below its 52-week high of 15.24, set on Jul 01, 2020.
5.39Mar 19 202015.24Jul 01 2020
Markit short selling activity
|Market cap||8.29bn SEK|
|EPS (TTM)||-5.73 |
Data delayed at least 15 minutes, as of Jul 08 2020.